Sino Biopharm (01177): Patient enrollment completed for the Phase III clinical trial of Vicetokumab 'CLDN18.2 ADC'.

Sino Biopharm (01177) announced that LM Rui Pharmatech (Shanghai) Co., Ltd. (LM Rui Pharma), a wholly-owned subsidiary of the group, has independently developed an innovative Class 1 national drug, Vitekotubomab (R&D code: LM-302), a 'CLDN18.2 ADC,' which is currently undergoing a Phase III registrational clinical trial (LM302-03-101) for the treatment of third-line and above CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma. Patient enrollment has been successfully completed. Notably, LM302 is the world's first CLDN18.2 ADC drug to complete patient enrollment in a Phase III registrational clinical trial.

Zhitong Finance06:15

Stock Movement | Sino Biopharm (01177) Rises Over 3% as Vicetoclax Monoclonal Antibody “CLDN18.2 ADC” Phase III Clinical Trial Completes Patient Enrollment

Sino Biopharm (01177) surged over 3%. As of the time of writing, it was up 3.09%, trading at HKD 6.68 with a turnover of HKD 149 million.

Zhitong Finance10:54

MIIT: By 2030, a preliminary collaborative development system for the entire industrial chain of traditional Chinese medicine will be established.

The Ministry of Industry and Information Technology and seven other departments released the 'Implementation Plan for High-Quality Development of the Traditional Chinese Medicine (TCM) Industry (2026-2030)', proposing that by 2030, a preliminary collaborative development system for the entire TCM industrial chain will be formed. The continuous and stable supply capacity of key TCM raw materials will be further enhanced, and the levels of digital intelligence and green practices will significantly improve. Breakthroughs will be achieved in a number of key technologies, and the level of industrial collaborative innovation will notably increase. Development quality will markedly improve, with steady growth in the scale and benefits of the TCM industry, and a clear rise in the degree of industrial intensification. Quality management standards will significantly improve, fostering a group of leading TCM industrial enterprises with outstanding leadership capabilities, as well as cultivating 60 high-quality products

AASTOCKSFeb 5 17:06

The Cyberspace Administration of China is intensifying its efforts to address false and misleading online information related to the centralized procurement of pharmaceuticals and medical consumables.

The Cyberspace Administration of China (CAC), in collaboration with the National Healthcare Security Administration (NHSA), has recently intensified efforts to address online false and misleading information related to bulk procurement of pharmaceuticals. A number of accounts that have tarnished the reputation of centralized procurement, incited public anxiety, or misled the public have been dealt with according to relevant laws and regulations. Examples of typical cases include: fabricating false information to defame centralized procurement policies for the purpose of gaining traffic;煽动社会情绪，制造公众焦虑；and deliberately associating non-procurement products with centralized procurement to mislead the public. The relevant accounts have already been subjected to appropriate measures as per legal and regulatory frameworks. The CAC emphasized that policies on the bulk procurement of medicines and medical consumables are closely tied to the vital interests of the public, and the fabrication and dissemination of false o

AASTOCKSFeb 5 11:39

The National Medical Products Administration (NMPA) announced that it will provide substantial support for the innovation and development of the bio-manufacturing industry during the 15th Five-Year Plan period.

The National Medical Products Administration (NMPA) stated that during the 15th Five-Year Plan period, it will strongly support innovation and development in the biomanufacturing industry, promoting the transformation of the pharmaceuticals industry from 'follow-up innovation' to 'systematic innovation,' from 'scale-and-speed-driven growth' to 'quality-and-efficiency-driven growth,' and from 'traditional business models' to 'digitalized supply chains.' The authority noted that this year, the country will closely monitor frontier technology areas such as new target and mechanism-based drugs, AI-driven drug discovery, as well as cell and gene therapies. Through four expedited approval pathways, the NMPA aims to accelerate drug market entry. Additionally, efforts will be made to effectively implement a data protection system for clinical trial data and establish policies specifically targeting pediatric medicines and treatments for rare diseases.

AASTOCKSFeb 4 17:42

The Hang Seng Index closed down 611 points, with pressure on commodity, telecom, chip, and auto stocks.

The commodity markets remained volatile during the Asian trading session, with Hong Kong stocks declining. The Hang Seng Index (HSI) opened 289 points lower and extended its losses, plunging as much as 879 points to reach an intraday low of 26,507 points. By the close, the HSI had fallen 611 points, or 2.2%, to settle at 26,775 points. The Hang Seng China Enterprises Index (HSCEI) dropped 236 points, or 2.5%, to close at 9,080 points, while the Hang Seng Tech Index declined by 191 points, or 3.4%, ending at 5,526 points. Total market turnover for the day reached HKD 347.886 billion. Gold and silver prices continued their decline, with Shandong Gold (01787.HK) plummeting 12.6%, China Silver Group (00815.HK), Zhaojin Mining (01818.HK), and China Gold International Resources also experiencing significant declines.

AASTOCKSFeb 2 16:35